Sinopharm Group Past Earnings Performance
Past criteria checks 2/6
Sinopharm Group has been growing earnings at an average annual rate of 8.7%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 8.8% per year. Sinopharm Group's return on equity is 11.4%, and it has net margins of 1.5%.
Key information
8.7%
Earnings growth rate
8.1%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 8.8% |
Return on equity | 11.4% |
Net Margin | 1.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sinopharm Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 590,346 | 8,653 | 26,802 | 0 |
31 Mar 24 | 598,415 | 9,315 | 26,996 | -96 |
31 Dec 23 | 596,570 | 9,054 | 26,775 | 0 |
30 Sep 23 | 594,526 | 9,248 | 27,158 | -210 |
30 Jun 23 | 591,626 | 8,936 | 26,657 | 0 |
31 Mar 23 | 570,067 | 8,688 | 25,995 | 34 |
31 Dec 22 | 552,148 | 8,526 | 25,346 | 0 |
30 Sep 22 | 546,147 | 7,914 | 24,584 | 84 |
30 Jun 22 | 533,403 | 7,870 | 24,276 | 0 |
31 Mar 22 | 528,383 | 7,970 | 23,884 | 19 |
31 Dec 21 | 521,051 | 7,759 | 23,656 | 0 |
30 Sep 21 | 507,611 | 7,847 | 23,439 | 126 |
30 Jun 21 | 501,770 | 7,874 | 23,652 | 0 |
31 Mar 21 | 474,798 | 6,956 | 22,643 | 42 |
31 Dec 20 | 456,415 | 7,187 | 21,873 | 0 |
30 Sep 20 | 442,674 | 6,698 | 21,745 | -97 |
30 Jun 20 | 427,372 | 6,174 | 20,430 | 0 |
31 Mar 20 | 431,976 | 6,554 | 20,442 | -33 |
31 Dec 19 | 425,273 | 6,251 | 19,797 | 0 |
30 Sep 19 | 406,394 | 6,311 | 18,856 | 22 |
30 Jun 19 | 382,717 | 6,012 | 18,128 | 0 |
31 Mar 19 | 360,760 | 6,087 | 16,903 | 11 |
31 Dec 18 | 344,526 | 5,834 | 16,235 | 0 |
30 Sep 18 | 336,113 | 5,523 | 15,420 | 75 |
30 Jun 18 | 334,060 | 5,606 | 15,580 | 0 |
31 Mar 18 | 318,414 | 5,083 | 14,416 | 22 |
31 Dec 17 | 308,354 | 5,572 | 13,353 | 0 |
30 Sep 17 | 288,855 | 5,217 | 12,094 | 0 |
30 Jun 17 | 269,356 | 4,861 | 10,836 | 0 |
31 Mar 17 | 264,691 | 4,996 | 10,875 | 0 |
31 Dec 16 | 258,388 | 4,635 | 10,744 | 0 |
30 Sep 16 | 251,401 | 4,515 | 10,512 | 0 |
30 Jun 16 | 244,414 | 4,394 | 10,279 | 0 |
31 Mar 16 | 234,499 | 3,885 | 9,964 | 0 |
31 Dec 15 | 228,673 | 3,772 | 9,755 | 0 |
30 Sep 15 | 222,513 | 3,548 | 9,504 | 0 |
30 Jun 15 | 216,353 | 3,323 | 9,254 | 0 |
31 Mar 15 | 207,865 | 3,037 | 8,890 | 0 |
31 Dec 14 | 200,131 | 2,875 | 8,681 | 0 |
30 Sep 14 | 190,883 | 2,719 | 8,447 | 0 |
30 Jun 14 | 181,635 | 2,564 | 8,212 | 0 |
31 Mar 14 | 174,251 | 2,407 | 7,899 | 0 |
31 Dec 13 | 166,866 | 2,250 | 7,586 | 0 |
Quality Earnings: SHTD.Y has high quality earnings.
Growing Profit Margin: SHTD.Y's current net profit margins (1.5%) are lower than last year (1.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SHTD.Y's earnings have grown by 8.7% per year over the past 5 years.
Accelerating Growth: SHTD.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SHTD.Y had negative earnings growth (-3.2%) over the past year, making it difficult to compare to the Healthcare industry average (10.3%).
Return on Equity
High ROE: SHTD.Y's Return on Equity (11.4%) is considered low.